Biogen Inc said on Friday it has decided to withdraw the marketing authorization application for its troubled Alzheimer's drug, aducanumab, in Europe after it failed to convince the regulator of the ...
Source LinkBiogen Inc said on Friday it has decided to withdraw the marketing authorization application for its troubled Alzheimer's drug, aducanumab, in Europe after it failed to convince the regulator of the ...
Source Link
Comments